Amneal Pharmaceuticals (AMRX) revenue breakdown
By segment, Affordable Medicines is the largest at 58% of fiscal 2025 revenue; AvKARE grew fastest, 20% a year over 5 years.
By region, US is the largest at 99% of fiscal 2019 revenue, growing -0% a year over 1 years.
Revenue by segment
Fiscal years, as Amneal Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $3.0B.
| Segments | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | $1.4B | $1.3B | $1.3B | $1.4B | $1.4B | $1.5B | $1.7B | $1.7B | 58% |
| AvKARE | — | — | $294M | $349M | $406M | $532M | $663M | $745M | 25% |
| Specialty | $224M | $318M | $356M | $378M | $374M | $390M | $446M | $529M | 18% |
Revenue by region
Fiscal years, as Amneal Pharmaceuticals reports them in its 10-K filings; fiscal 2019 total $1.6B.
| Regions | 2018 | 2019 | Share |
|---|---|---|---|
| US | $1.6B | $1.6B | 99% |
| International | $60M | $21M | 1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AMRX.
Open AMRX in InvestinglyQuestions
Where does Amneal Pharmaceuticals make its money?
In fiscal 2025, by segment: Affordable Medicines $1.7B, AvKARE $745M, Specialty $529M.
From Amneal Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.